{
  "id": "601dbe101cb411341a00004c",
  "type": "factoid",
  "question": "What is the brand name for erenumab?",
  "ideal_answer": "Aimovig (erenumab; erenumab-aooe in the United States) is the only US Food and Drug Administration (FDA)-approved monoclonal antibody (mAb) therapy against the CGRP receptor (CGRPR) for the prevention of migraine.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/32049005",
    "http://www.ncbi.nlm.nih.gov/pubmed/29968151",
    "http://www.ncbi.nlm.nih.gov/pubmed/32259079",
    "http://www.ncbi.nlm.nih.gov/pubmed/32753854"
  ],
  "snippets": [
    {
      "text": "Aimovig (erenumab; erenumab-aooe in the United States) is the only US Food and Drug Administration (FDA)-approved monoclonal antibody (mAb) therapy against the CGRP receptor (CGRPR) for the prevention of migraine",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32049005",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Erenumab-aooe (erenumab, Aimovig\u00ae)-a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide (CGRP) receptor-is approved for the prevention of migraine in adults in a number of countries",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32753854",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Purpose: Erenumab-aooe (erenumab, Aimovig\u00ae)-a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide (CGRP) receptor-is approved for the prevention of migraine in adults in a number of cou",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32753854",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Amgen and Novartis are developing erenumab (AIMOVIG\u2122, erenumab-aooe)-a fully human monoclonal antibody calcitonin gene-related peptide (CGRP) receptor antagonist-for the prevention of migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29968151",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Aimovig (erenumab; erenumab-aooe in the United States) is the only US Food and Drug Administration (FDA)-approved monoclonal antibody (mAb) therapy against the CGRP receptor (CGRPR) for the prevention of migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32049005",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Discovery of the Migraine Prevention Therapeutic Aimovig (Erenumab), the First FDA-Approved Antibody against a G-Protein-Coupled Receptor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32259079",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In 2018, the United States Food and Drug Administration (FDA) approved Aimovig (erenumab) for the prevention of migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32259079",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Purpose: Erenumab-aooe (erenumab, Aimovig\u00ae)-a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide (CGRP) receptor-is approved for the prevention of migraine in adults in a number of c",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32753854",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Aimovig"
}